Pharmacology should be at the centre of all preclinical and clinical studies on new psychoactive substances (recreational drugs)

Journal of Psychopharmacology

Volumn 28, Issue 8, 2014, Pages 711-718

  Green, A Richard ^a   Nutt, David J ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

3,4 methylenedioxymethamphetamine; Ecstasy; integrative pharmacology; mephedrone; new psychoactive substances; pharmacokinetics; quantitative pharmacology; recreational drugs

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 HYDROXYBUTYRIC ACID; 4' METHYLMETHCATHINONE; ALCOHOL; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CAFFEINE; CANNABIS; COCAINE; KETAMINE; LYSERGIDE; NICOTINE; OPIATE; PSILOCYBINE; PSYCHOTROPIC AGENT; RECREATIONAL DRUG; STREET DRUG;

AREA UNDER THE CURVE; CLINICAL STUDY; CONCENTRATION (PARAMETERS); HUMAN; INGESTION; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXICOLOGY; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG INTERACTION; DRUG SCREENING; PROCEDURES;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; HUMANS; STREET DRUGS;

EID: 84904632760     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881114528593     Document Type: Review

References (70)

1. Aarde SM, Angrish D, Barlow DJ, et al. Mephedrone (4-methylmethcathinone) supports intravenous self-administration in Sprague-Dawley and Wistar rats. Addict Biol. 2013 ; 18: 786-799
2. Allott K, Redman J. Are there sex differences associated with the effects of ecstasy/3,4-methylenedioxymethamphetamine (MDMA)?. Neurosci Biobehav Rev. 2007 ; 31: 327-347
3. Angoa-Pérez M, Kane MJ, Briggs DI, et al. Mephedrone does not damage dopamine nerve endings of the striatum, but enhances the neurotoxicity of methamphetamine, amphetamine, and MDMA. J Neurochem. 2013 ; 125: 102-110
4. Bath PM, Macleod MR, Green AR. Emulating multicentre clinical stroke trials: A new paradigm for studying novel interventions in experimental models of stroke. Int J Stroke. 2009a ; 4: 471-479
5. Bath PMW, Gray LJ, Bath AJG, et al. Effects of NXY-059 in experimental stroke: An individual animal meta-analysis. Br J Pharmacol. 2009b ; 157: 1157-1171
6. Baumann MH, Zolkowska D, Kim I, et al. Effects of dose and route of administration on pharmacokinetics of (±)-3,4- methylenedioxymethamphetamine (MDMA) in the rat. Drug Metab Dispos. 2009 ; 37: 2163-2170
7. British Pharmacological Society (2013) Available at: http://www.bps.ac. uk/details/news/5241751/Leading-societies-support-ethically-correct-publication- of-negative-findings.html (accessed 12 March 2014).
8. Brunt TM, Poortman A, Niesink RJM, et al. Instability of the ecstasy market and a new kid on the block: Mephedrone. J Psychopharmacol. 2011 ; 25: 1543-1547
9. Cameron K, Kolanos R, Verkariya R, et al. Mephedrone and methylenedioxypyrovalerone (MDPV), major constituents of 'bath salts,' produce opposite effects at the human dopamine transporter. Psychopharmacology. 2013 ; 227: 493-499
10. Carhart-Harris RL, King LA, Nutt DJ. A web-based survey on mephedrone. Drug Alcohol Depend. 2011 ; 118: 19-22
11. Cole JC, Sumnall HR. Altered states: The clinical effects of 'ecstasy'. Pharmacol Ther. 2003 ; 98: 35-58
12. Curran HV. Is MDMA ('ecstasy') neurotoxic in humans? An overview of evidence and of methodological problems in research. Neuropsychobiology. 2000 ; 42: 34-41
13. Dargan PI, Albert S, Wood DM. Mephedrone use and associated adverse effects in school and college/university students before the UK legislation change. QJM. 2010 ; 103: 875-879
14. Dargan PI, Sedefov R, Gallegos A, et al. The pharmacology and toxicology of the synthetic cathinone mephedrone (4-methylmethcathinone). Drug Test Anal. 2011 ; 3: 454-463
15. De la Torre R, Farré M. Neurotoxicity of MDMA (ecstasy): The limitations of scaling from animals to humans. Trends Pharmacol Sci. 2004 ; 25: 505-508
16. De la Torre R, Puerta E, Aguirre N. Comment on the letter by Green, Gabrielsson, Marsden, Fone, MDMA: On the translation from rodent to human dosing. Psychopharmacology. 2009 ; 204: 379-380
17. Docherty JR, Green AR. The role of monoamines in the changes in body temperature induced by 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its derivatives. Br J Pharmacol. 2010 ; 160: 1029-1044
18. Fallon JK, Kicman AT, Henry JA, et al. Stereospecific analysis and enantiomeric disposition of 3,4-methylenedioxymethamphetamine (Ecstasy) in humans. Clin Chem. 1999 ; 45: 1058-1069
19. Farré M, Abanades S, Roset PN, et al. Pharmacological interaction between 3,4 and methylenedioxymethamphetamine (ecstasy) and paroxetine: Pharmacological effects and pharmacokinetics. J Pharmacol Exp Ther. 2007 ; 323: 954-962
20. Gabrielsson J, Green AR. Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology. J Pharmacol Exp Ther. 2009 ; 331: 767-774
21. Gabrielsson J, Green AR, Van der Graaf PH. Optimising in vivo pharmacology studies-practical PKPD considerations. J Pharmacol Toxicol Methods. 2010 ; 61: 146-156
22. Grahame-Smith DG, Aronson JK Oxford Textbook of Clinical Pharmacology and Drug Therapy. Oxford: Oxford University Press ; 1995 :
23. Green AR, Aronson JK. From basic to clinical neuropharmacology: Targetophilia or pharmacodynamics?. Br J Clin Pharmacol. 2012 ; 73: 959-967
24. Green AR, Gabrielsson J, Fone KC. Translational neuropharmacology and the appropriate and effective use of animal models. Br J Pharmacol. 2011 ; 164: 1041-1043
25. Green AR, Gabrielsson J, Marsden CA, et al. MDMA: On the translation from rodent to human dosing. Psychopharmacology. 2009 ; 204: 375-378
26. Green AR, King MV, Shortall SE, et al. Lost in translation: Preclinical studies on 3,4-methylenedioxymethamphetamine provide information on mechanisms of action, but do not allow accurate prediction of adverse events in humans. Br J Pharmacol. 2012 ; 166: 1523-1536
27. Green AR, King MV, Shortall SE, et al. The preclinical pharmacology of mephedrone; not just MDMA by another name. Br J Pharmacol. 2014 ;:
28. Green AR, Mechan AO, Elliott JM, et al. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'). Pharmacol Rev. 2003 ; 55: 463-508
29. Green AR, O'Shea E, Saadat KS, et al. Studies on the effect of MDMA ('ecstasy') on the body temperature of rats housed at different ambient room temperatures. Br J Pharmacol. 2005 ; 146: 306-312
30. Hamida SB, Tracqui A, de Vasconcelos AP, et al. Ethanol increases the distribution of MDMA to the rat brain: Possible implications in the ethanol-induced potentiation of the psychostimulant effects of MDMA. Int J Neuropsychopharmacol. 2009 ; 12: 749-759
31. James D, Adams RD, Spears R, et al. Clinical characteristics of mephedrone toxicity reported to the U.K. National Poisons Information Service. Emerg Med J. 2011 ; 28: 686-689
32. Joksovic P, Mellos N, van Wattum PJ, et al. 'Bath salts'-induced psychosis and serotonin toxicity. J Clin Psychiatry. 2012 1125 ; 73 :
33. Kalechstein AD, De La Garza R, Mahoney JJ, et al. MDMA use and neurocognition: A meta-analytic review. Psychopharmacology. 2007 ; 189: 531-537
34. Laws KR, Kokkalis J. Ecstasy (MDMA) and memory function: A meta-analytic update. Hum Psychopharmacol. 2007 ; 22: 381-388
35. McGrath JC, Drummond GB, McLachlan EM, et al. Guidelines for reporting experiments involving animals: The ARRIVE Guidelines. Br J Pharmacol. 2010 ; 160: 1573-1576
36. Martínez-Clemente J, López-Arnau R, Carbó M, et al. Mephedrone pharmacokinetics after intravenous and oral administration in rats: Relation to pharmacodynamics. Psychopharmacology. 2013 ; 229: 295-306
37. Maskell PD, De Paoli G, Seneviratne C, et al. Mephedrone (4-methylmethcathinone)-related deaths. J Anal Toxicol. 2011 ; 35: 188-191
38. Miller ML, Creehan KM, Angrish D, et al. Changes in ambient temperature differentially alter the thermoregulatory, cardiac and locomotor stimulant effects of 4-methylmethcathinone (mephedrone). Drug Alcohol Depend. 2013 ; 127: 248-253
39. Mohamed WMY, Hamida SB, Cassel J-C, et al. MDMA: Interactions with other psychoactive drugs. Pharmacol Biochem Behav. 2011 ; 99: 759-774
40. Moore K, Dargan PI, Wood DM, et al. Do novel psychoactive substances displace established club drugs, supplement them or act as drugs of initiation? The relationship between mephedrone, ecstasy and cocaine. Eur Addict Res. 2013 ; 19: 276-282
41. Morefield KM, Keane M, Felgate P, et al. Pill content, dose and resulting plasma concentrations of 3,4-methylendioxymethamphetamine (MDMA) in recreational 'ecstasy' users. Addiction. 2011 ; 106: 1293-1300
42. Murphy PN, Bruno R, Ryland I, et al. The effects of 'ecstasy' (MDMA)on visuospatial memory performance: Findings from a systematic review with meta-analyses. Hum Psychopharmacol. 2012 ; 27: 113-138
43. Nulsen CE, Fox AM, Hammond GR. Differential effects of ecstasy on short-term and working memory: A meta-analysis. Neuropsychol Rev. 2010 ; 20: 21-32
44. Nutt DJ, King LA, Nichols DE. Effects of Schedule I drug laws on neuroscience research and treatment innovation. Nat Rev Neurosci. 2013 ; 14: 577-585
45. O'Shea E, Granados R, Esteban B, et al. The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA ('ecstasy'). Neuropharmacology. 1998 ; 37: 919-926
46. Parrott AC. MDMA, serotonergic neurotoxicity, and the diverse functional deficits of recreational 'Ecstasy' users. Neurosci Biobehav Rev. 2013 ; 37: 1466-1484
47. Regan L, Mitchelson M, Macdonald C. Mephedrone toxicity in a Scottish emergency department. Emerg Med J. 2011 ; 28: 1055-1058
48. Sanchez V, O'Shea E, Saadat KS, et al. Effect of repeated ('binge') dosing of MDMA to rats housed at normal and high temperature on neurotoxic damage to cerebral 5-HT and dopamine neurones. J Psychopharmacol. 2004 ; 18: 412-416
49. Schifano F, Albanese A, Fergus S, et al. Mephedrone (4- methylmethcathinone; 'meow meow'): Chemical, pharmacological and clinical issues. Psychopharmacology. 2011 ; 214: 593-602
50. Schifano F, Corkery J, Ghodse AH. Suspected and confirmed fatalities associated with mephedrone (4-methylmethcathinone, 'meow meow') in the United Kingdom. J Clin Psychopharmacol. 2012 ; 32: 710-714
51. Sena E, van der Worp BH, Howells DW, et al. How can we improve the pre-clinical development of drugs for stroke?. Trends Neurosci. 2007 ; 30: 432-439
52. Sena ES, van der Worp HB, Bath PM, et al. Publication bias in reports of animal stroke studies leads to major overstatement of efficacy. PLoS Biol. 2010 ; 8: e1000344
53. Shortall SE, Green AR, Swift KM, Fone KC, King MV. Differential effects of cathinone compounds and MDMA on body temperature in the rat, and pharmacological characterization of mephedrone-induced hypothermia. Br J Pharmacol. 2013a ; 168: 966-977
54. Shortall SE, Macerola AE, Swaby RT, et al. Behavioural and neurochemical comparison of chronic intermittent cathinone, mephedrone and MDMA administration to the rat. Eur Neuropsychopharmacol. 2013b ; 23: 1085-1095
55. Shortall SE, Byatt S, Kaufman N, et al. Caffeine alters the behavioural and thermoregulatory responses to mephedrone without causing long-term neurotoxicity. J Psychopharmacol. 2013c ; 27: A63
56. Sjoerdsma AG Starting with Serotonin. Silver Spring Maryland, USA: Improbable Books ; 2008 :
57. Sumnall HR, Cole JC. Self-reported depressive symptomatology in community samples of polysubstance misusers who report Ecstasy use: A meta-analysis. J Psychopharmacol. 2005 ; 19: 84-92
58. Taylor EM, Greene NM, Morgan CJ, et al. Association of study characteristics with estimates of effect size in studies of ecstasy use. Psychopharmacology. 2011 ; 25: 1573-1577
59. Tucker GT, Lennard MS, Ellis SW, et al. The demethylenation of methylenedioxymethamphetamine ('ecstasy') by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol. 1994 ; 47: 1151-1156
60. United Nations office on Drugs and Crime (UNODC) (2013) World Drug Report. Available at: www.unodc.org/unodc/secured/wdr/wdr2013/World-Drug-Report- 2013.pdf (accessed 12 March 2014).
61. Vanattou-Saïfoudine N, McNamara R, Harkin A. Caffeine provokes adverse interactions with 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and related psychostimulants: Mechanisms and mediators. Br J Pharmacol. 2012 ; 167: 946-959
62. Verbaten MN. Deterioration of executive functioning in chronic ecstasy users; evidence for multiple drugs effects. Curr Drug Abuse Rev. 2010 ; 3: 129-138
63. Verheyden SL, Hadfield J, Calin T, et al. Sub-acute effects of MDMA (+/-3,4-methylenedioxymethamphetamine, 'ecstasy') on mood: Evidence of gender differences. Psychopharmacology. 2002 ; 161: 23-31
64. Vogels N, Brunt TM, Rigter S, et al. Content of ecstasy in the Netherlands: 1993-2008. Addiction. 2009 ; 104: 2057-2066
65. Winstock A, Mitcheson L, Ramsey J, et al. Mephedrone: Use, subjective effects and health risks. Addiction. 2011 ; 106: 1991-1996
66. Wood DM, Dargan PI. Mephedrone (4-methylmethcathinone): What is new in our understanding of its use and toxicity. Prog Neuropsychopharmacol Biol Psychiatry. 2012 ; 39: 227-233
67. Wood DM, Greene SL, Dargan PI. Clinical pattern of toxicity associated with the novel synthetic cathinone mephedrone. Emerg Med J. 2011 ; 28: 280-282
68. Wright MJ Jr, Angrish D, Aarde SM, et al. Effect of ambient temperature on the thermoregulatory and locomotor stimulant effects of 4-methylmethcathinone in Wistar and Sprague-Dawley rats. PLoS One. 2012 ; 7: e44652
69. Yang J, Jamei M, Heydarri A, et al. Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA. J Psychopharmacol. 1996 ; 20: 842-849
70. Zawilska JB, Wojcieszak J. Designer cathinones-An emerging class of novel recreational drugs. Forensic Sci Int. 2013 ; 231: 42-53